Inventor · disambiguated record
Jan Endell
Also filed as: ENDELL JAN
12 granted patents·9 pending applications·50 citations·filing 2011–2024
88Inventor score
Top patents by PatentIndex Score
21 records- 0193US12194095B2Combinations and uses thereofINCYTE CORP·Filed 2021·Granted Jan 14, 2025·2 cites·28 claims
- 0289US8877899B2Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHLROJKJAER LISA·Filed 2011·Granted Nov 4, 2014·25 cites·19 claims
- 0387US9289490B2Combinations and uses thereofMORPHOSYS AG·Filed 2014·Granted Mar 22, 2016·10 cites·20 claims
- 0485US11224654B2Combinations and uses thereofMORPHOSYS AG·Filed 2016·Granted Jan 18, 2022·2 cites·18 claims
- 0581US10617691B2Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2016·Granted Apr 14, 2020·3 cites·16 claims
- 0681US2025195646A1Combinations and uses thereofINCYTE CORP·Filed 2024·Application pending·0 cites
- 0778US9765152B2Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomibMORPHOSYS AG·Filed 2016·Granted Sep 19, 2017·2 cites·14 claims
- 0877US9579378B2Combinations and uses thereofMORPHOSYS AG·Filed 2013·Granted Feb 28, 2017·4 cites·16 claims
- 0974US10308722B2Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomideMORPHOSYS AG·Filed 2017·Granted Jun 4, 2019·1 cites·20 claims
- 1074US2024009196A1Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2023·Application pending·0 cites
- 1171US2022283166A1Methods for predicting therapeutic benefit of anti-cd19 therapy in patientsMORPHOSYS AG·Filed 2022·Application pending·0 cites
- 1270US10533057B2Treatment for multiple myeloma (MM)MORPHOSYS AG·Filed 2016·Granted Jan 14, 2020·1 cites·5 claims
- 1368US11591406B2Treatment for multiple myeloma (MM)MORPHOSYS AG·Filed 2019·Granted Feb 28, 2023·0 cites·7 claims
- 1462US2020206228A1Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1556US2023014026A1Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune CheckpointMORPHOSYS AG·Filed 2021·Application pending·0 cites
- 1656US2019195879A1Methods for predicting therapeutic benefit of anti-cd19 therapy in patientsMORPHOSYS AG·Filed 2017·Application pending·0 cites
- 1752US2024156863A1Sequential anti-cd19 therapyMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1852US2021130461A1Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cellsMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1951US12491244B2Pharmaceutical combinations for treating tumor comprising anti-CD19 antibody and natural killer cellGC CELL CORP·Filed 2019·Granted Dec 9, 2025·0 cites·23 claims
- 2050US2022242952A1Anti-cd19 therapy in patients having a limited number of nk cellsMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 2143US12358983B2Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereofINCYTE CORP·Filed 2017·Granted Jul 15, 2025·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when Jan Endell files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →